At the Clinical Cardiology Institute in Rome First Implantation

At the Clinical Cardiology Institute in Rome First Implantation of the World’s Lonterst and Most Revolutionary pacemaker

First Implantation at ICC (Cardiological Clinical Institute) in Rome of the world’s dispos and moust revolutionary pacemaker, The Micra Tps. The surgery, performed in just 20 minutes on a 75-year-old patient suffering from Chronic Atrial Fibrillation, was completed by the medical team led by Dr. Saverio Iacopino, National Coordinator of the Arrhythmology Unit at GVM Care & Research, a Group of Which Ic, to Private High Specialty Hospital, is a member.

Distrarged Only 24 Hours After Admission, The Man Is Now Well and Has Returned To His Family to Resume Daily Routines. The Procedure Required no Surgical Cuts or General Aesthesia. The Device Will Be Remotelly Controlled via A Special Monitoring Unit Capable of Recording Every Sllightest Variation.

The MicraDr. Iacopino ExplainsRepresents One of the Most Advanced and Innovative Technological Solutions for the Nonsurgical Treatment of Severe Heart Rhythm Alterazions Resulting from Dysfunction of the Heart’s Internal Electrical System. The Man, WHO WAS affected by the permanent (Chronic) Form of the Disease and Who Present, On Holter ECG EXAMINATION, WITH REPEATED PATHOLOGAL PAUSES IN THE HEARTBEAT, HAD Faced a Previous Hospitalization for Replacement of the Natural Aortic Valve with a New Artificial Valve. The micra implantation made it possible to shelter the patient from the risk of asystole (total apsence of pulse) and thus from weapon electrical organ shutdown.”.

Atrial FibrillationClarifies Dr. IacopinoIs an insidious entrythmia. IT Affects About 1% of the population, and the likelihyo of diagnosing the condition incaases with advancing age. The Irregularity of the Heartbeat, Typical of the Disease, Causes Ineffective Contraction of the Atrial Cavities, Which in Turn Affects the Work of the Ventricles and Blood Flow: The Result Is a Very Distresses Heart.

Associated with this is the possible formation of clots that ounces in the Bloodstream causes cerebral ischemia or stroke“.

The MicraDr. Iacopino Points OutFinds Use in Clinical Cases Similar to the One Described and is a pacemaker with revolutionary features, to say the least. It weighs just 2 grams, is MRI compatible up to 3 Tesla, and does not need electrodes pushed into the body circulation to work. It features in Long-Lasting Miniaturized Battery with a Projected Longevity of More Than 12 Years: The Implant Requires No Surgical Cutting. It is injected through the femorral vein, at the level of the grin, and advanced, Taking Advancer of the use of a Steerable Guide and Under Constant Fluoroscopic Control, to the Apex of the Right Ventricle. It is then docked and attacked to the heart tissue Thanks to tiny metal staples.

Application Requires No General Aesthesia, Only Local Aesthesia at the Site of Device Insertion. The Entire procedures is complete in less than 30 minutes“.

The advantages of Micra are many: there is no surgical stress since traditional surgery is not used; hospital stay times are drastically reduced; in worldwide case histories, more than 90 percent of treated patients do not experience major complications; the absence of scars on the chest does not induce cosmetic discomfort, and the patient almost does not feel that he or she has undergone surgery. It can also be retrieved and reposition in the course of the intervention by means of a special system.

It is now amply demonstrated by clinical evidence how the micra repireseaven a True Revolution in the field of permanent cardiac electrostimulationDr. Iacopino concludesAS IT ENABLES EFFECTIVE VENTRICULAR PACING WHILE AVOIDING PROBLEMS Related to Lead Performance and Infection of Implantable Devices. Leadless Technology, in fact, Allaws the interventional electrophysiologist to proposed to Useful alternatives to conventional cardiostimulation in selected subjects in whom the benefit of the micra system clearly outweighs the procedural Risks, which are in any case limited and statistically insignificant“.

The Micra is used in the Hospital Facilities of GVM Care & Research, Among the First Centers in Europe, by the Team Led by Dr. Iacopino. Saverio Iacopino who has performed the most interventions in Italy. Seventy Patient to Date Have Benefited from the New Technology with 100% subsequent at Device Implantation: No Complications, No Infection or Doslocation (Displacement From The Apex of the Right Ventricle).